<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115570</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6096</org_study_id>
    <secondary_id>HMR 1964</secondary_id>
    <nct_id>NCT00115570</nct_id>
  </id_info>
  <brief_title>Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents</brief_title>
  <official_title>Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and
      effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with
      type 1 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint</measure>
    <time_frame>week 26 or last observed treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GHb at weeks 12 and 26</measure>
    <time_frame>weeks 12 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Self-monitored glucose parameters</measure>
    <time_frame>weeks 4, 12, 18, 26, and endpoint;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Symptomatic hypoglycemia</measure>
    <time_frame>first dose of study up to last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in basal insulin dose</measure>
    <time_frame>week 4, 12, 18, 26, and endpoint;</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">572</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Insulin Glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Insulin Glulisine</arm_group_label>
    <other_name>apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin lispro</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Subcutaneous injection once daily</description>
    <arm_group_label>Insulin Glulisine</arm_group_label>
    <arm_group_label>Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>subcutaneous injection twice daily</description>
    <arm_group_label>Insulin Glulisine</arm_group_label>
    <arm_group_label>Insulin Lispro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Girls/boys, 4-17 years, inclusive;

          -  Girls not yet of childbearing potential or, if sexually active, agree to use reliable
             medically accepted contraceptive measure during study;

          -  Type 1 diabetes mellitus established in medical history: for example, but not limited
             to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss,
             ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of
             type 1 diabetes measured at any time before study; or requiring continuous insulin
             therapy from time of diagnosis;

          -  Onset of diabetes at least 1 year prior to visit 1 (V1) of study;

          -  Uninterrupted insulin therapy for at least 1 year before V1 of study;

          -  At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin
             and willing to have multiple daily injections of insulin;

          -  Glycated hemoglobin at V1 between ≥ 6.0 and ≤11.0 %;

          -  Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer
             and subject diary.

        Exclusion Criteria:

          -  Active proliferative diabetic retinopathy, defined by application of focal or
             panretinal photocoagulation or vitrectomy, 6 months before V1, or any other
             unstable/rapidly progressing retinopathy requiring surgical treatment (including laser
             photocoagulation) during study;

          -  Diabetes other than type 1 diabetes mellitus;

          -  Pregnancy (positive pregnancy blood test at V1) or breastfeeding;

          -  Pancreatectomized subjects;

          -  Subjects who have had pancreas and/or islet cell transplants;

          -  Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;

          -  Treatment with systemic corticosteroids in last month before V1;

          -  Subjects on pump therapy during last 2 months before V1;

          -  Subjects requiring excessively high doses of insulin (&quot;resistant&quot; patients), for
             example, but not limited to, subjects receiving over 150 IU per day;

          -  Likelihood of needing treatment during study period with drugs not permitted by
             protocol

          -  Treatment with any investigational drug in last month before V1;

          -  History of primary seizure disorders;

          -  History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic
             ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior
             to V1;

          -  History of hypoglycemia unawareness;

          -  History of hypersensitivity to insulin or insulin analogs or any of the excipients in
             insulin glulisine formulation or any of the excipients in other study insulin
             preparations formulations;

          -  Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major
             systemic disease making implementation of protocol or interpretation of study results
             difficult and would, in the opinion of the investigator, preclude safe participation
             of subject in protocol;

          -  History of cardiac abnormalities and/or cardiovascular disorders;

          -  History of drug/alcohol abuse;

          -  Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) greater than twice the normal upper limit for age
             at V1;

          -  Impaired renal function shown by, but not limited to, serum creatinine greater than
             1.5 times upper limit for age at V1;

          -  Non fasting triglyceride level of &gt;500 mg/dL (5.7 mmol/L) at V1;

          -  Parent/legally authorized representative unable to understand nature, scope, possible
             consequences of study;

          -  Parent/legally authorized representative unable to read/write;

          -  Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate
             in adequate training, uncooperative attitude, inability to return for follow-up
             visits, and unlikelihood of completing study;

          -  Children/relatives of employee of sponsor or of sponsor representatives;

          -  Children or relatives of investigator, any sub-investigator, research assistant,
             pharmacist, study coordinator or other staff directly involved in conduct of protocol;

          -  Subjects who have previously been treated with insulin glulisine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Arethi PHILOTHEOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2005</study_first_submitted>
  <study_first_submitted_qc>June 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2005</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes,Insulin-Dependent, pediatric,rapid acting injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

